Compare Stocks: MNPR, CLDX, IRON, and BEAM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$27.48 +0.8%	$30.61	$15.60 ▼ $38.26	$2.81B	2.23	2.05 million shs	1.32 million shs
CLDX Celldex Therapeutics	$41.71 +0.4%	$35.19	$19.72 ▼ $42.92	$3.26B	0.87	954,386 shs	808,912 shs
IRON Disc Medicine	$77.44	$73.59	$40.00 ▼ $99.50	$2.96B	1	351,184 shs	307,549 shs
MNPR Monopar Therapeutics	$119.21 -0.8%	$90.83	$29.18 ▼ $124.82	$805.29M	1.47	299,624 shs	223,298 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+0.84%	+7.68%	-25.49%	-14.98%	+50.16%
CLDX Celldex Therapeutics	+0.36%	+9.59%	+7.06%	+22.78%	+94.54%
IRON Disc Medicine	0.00%	+0.57%	-3.27%	+13.45%	+31.25%
MNPR Monopar Therapeutics	-0.83%	+10.02%	+20.09%	+87.50%	+193.26%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$27.48 +0.8%	$30.61	$15.60 ▼ $38.26	$2.81B	2.23	2.05 million shs	1.32 million shs
CLDX Celldex Therapeutics	$41.71 +0.4%	$35.19	$19.72 ▼ $42.92	$3.26B	0.87	954,386 shs	808,912 shs
IRON Disc Medicine	$77.44	$73.59	$40.00 ▼ $99.50	$2.96B	1	351,184 shs	307,549 shs
MNPR Monopar Therapeutics	$119.21 -0.8%	$90.83	$29.18 ▼ $124.82	$805.29M	1.47	299,624 shs	223,298 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+0.84%	+7.68%	-25.49%	-14.98%	+50.16%
CLDX Celldex Therapeutics	+0.36%	+9.59%	+7.06%	+22.78%	+94.54%
IRON Disc Medicine	0.00%	+0.57%	-3.27%	+13.45%	+31.25%
MNPR Monopar Therapeutics	-0.83%	+10.02%	+20.09%	+87.50%	+193.26%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	2.69	Moderate Buy	$49.00	78.31% Upside
CLDX Celldex Therapeutics	2.86	Moderate Buy	$55.46	32.97% Upside
IRON Disc Medicine	2.75	Moderate Buy	$106.00	36.88% Upside
MNPR Monopar Therapeutics	3.07	Buy	$112.08	-5.98% Downside

Current Analyst Ratings Breakdown

Latest MNPR, CLDX, IRON, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$40.00 ➝ $46.00
8/7/2026	CLDX Celldex Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $53.00
8/6/2026	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$118.00 ➝ $120.00
7/29/2026	CLDX Celldex Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $72.00
7/23/2026	MNPR Monopar Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$125.00
7/22/2026	CLDX Celldex Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$54.00 ➝ $48.00
7/22/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$44.00 ➝ $40.00
7/22/2026	CLDX Celldex Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$67.00 ➝ $61.00
7/22/2026	CLDX Celldex Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$62.00 ➝ $60.00
7/22/2026	MNPR Monopar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$105.00 ➝ $125.00
7/20/2026	CLDX Celldex Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$90.00 ➝ $100.00

(Data available from 8/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$139.74M	20.31	N/A	N/A	$10.34 per share	2.66
CLDX Celldex Therapeutics	$1.54M	2,125.86	N/A	N/A	$7.93 per share	5.26
IRON Disc Medicine	N/A	N/A	N/A	N/A	$16.88 per share	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$20.62 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$79.99M	-$0.86	N/A	N/A	N/A	-54.75%	-30.71%	-24.07%	N/A
CLDX Celldex Therapeutics	-$258.76M	-$4.26	N/A	N/A	N/A	N/A	-57.00%	-51.74%	N/A
IRON Disc Medicine	-$212.18M	-$6.58	N/A	N/A	N/A	N/A	-37.17%	-33.65%	N/A
MNPR Monopar Therapeutics	-$13.72M	-$1.90	N/A	N/A	N/A	N/A	-12.84%	-12.57%	8/11/2026 (Estimated)

Latest MNPR, CLDX, IRON, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	MNPR Monopar Therapeutics	-$0.6553	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	CLDX Celldex Therapeutics	-$1.06	-$0.94	+$0.12	-$0.94	$0.74 million	$0.02 million
8/4/2026	Q2 2026	BEAM Beam Therapeutics	-$1.11	-$1.18	-$0.07	-$1.18	$16.37 million	$0.49 million
7/30/2026	Q2 2026	IRON Disc Medicine	-$1.71	-$1.54	+$0.17	-$1.54	$1.00 million	N/A
5/14/2026	Q1 2026	MNPR Monopar Therapeutics	-$0.8703	-$0.46	+$0.4103	-$0.46	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	0.09	14.57	16.99
CLDX Celldex Therapeutics	N/A	8.92	8.92
IRON Disc Medicine	0.09	24.14	24.14
MNPR Monopar Therapeutics	N/A	56.04	56.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
CLDX Celldex Therapeutics	N/A
IRON Disc Medicine	83.70%
MNPR Monopar Therapeutics	1.83%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.80%
CLDX Celldex Therapeutics	5.20%
IRON Disc Medicine	3.76%
MNPR Monopar Therapeutics	9.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	103.29 million	99.36 million	Optionable
CLDX Celldex Therapeutics	150	78.49 million	74.41 million	Optionable
IRON Disc Medicine	30	38.16 million	36.73 million	Not Optionable
MNPR Monopar Therapeutics	10	6.70 million	6.05 million	Not Optionable

MNPR, CLDX, IRON, and BEAM Headlines

Recent News About These Companies

Monopar Therapeutics (NASDAQ:MNPR) Upgraded at Wall Street Zen

August 8 at 2:11 AM | marketbeat.com

Bank of New York Mellon Corp Has $4.31 Million Position in Monopar Therapeutics Inc. $MNPR

August 7 at 3:03 AM | marketbeat.com

Monopar Therapeutics (NASDAQ:MNPR) Sets New 1-Year High - What's Next?

August 6 at 10:59 AM | marketbeat.com

Monopar Therapeutics (MNPR) Projected to Post Earnings on Tuesday

August 4, 2026 | marketbeat.com

Monopar Therapeutics (NASDAQ:MNPR) Reaches New 52-Week High - What's Next?

July 31, 2026 | marketbeat.com

Monopar Therapeutics Inc. $MNPR Position Increased by ADAR1 Capital Management LLC

July 29, 2026 | marketbeat.com

Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Consensus Rating of "Buy" by Analysts

July 28, 2026 | americanbankingnews.com

Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Recommendation of "Buy" from Analysts

July 28, 2026 | marketbeat.com

HC Wainwright Has Positive Outlook of MNPR FY2027 Earnings

July 24, 2026 | marketbeat.com

Siren L.L.C. Increases Stake in Monopar Therapeutics Inc. $MNPR

July 24, 2026 | marketbeat.com

Walleye Capital LLC Takes Position in Monopar Therapeutics Inc. $MNPR

July 24, 2026 | marketbeat.com

Monopar Therapeutics (NASDAQ:MNPR) Stock Price Down 8.9% - What's Next?

July 23, 2026 | marketbeat.com

HC Wainwright Issues Positive Forecast for Monopar Therapeutics (NASDAQ:MNPR) Stock Price

July 22, 2026 | marketbeat.com

Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease

July 22, 2026 | globenewswire.com

Monopar Therapeutics (NASDAQ:MNPR) Sets New 12-Month High - What's Next?

July 20, 2026 | marketbeat.com

Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team

July 20, 2026 | globenewswire.com

Monopar: A Rare Disease Asset With Heavy-Metal Upside (Initiating Buy)

July 17, 2026 | seekingalpha.com

Monopar Therapeutics (NASDAQ:MNPR) Shares Up 6.8% - What's Next?

July 15, 2026 | marketbeat.com

Monopar Therapeutics (NASDAQ:MNPR) Upgraded at Zacks Research

July 15, 2026 | marketbeat.com

Monopar Therapeutics (NASDAQ:MNPR) Lowered to "Sell" Rating by Wall Street Zen

July 12, 2026 | marketbeat.com

Monopar Therapeutics (NASDAQ:MNPR) Hits New 12-Month High - Here's Why

July 9, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MNPR, CLDX, IRON, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$27.48 +0.23 (+0.84%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$27.70 +0.22 (+0.78%)

As of 08/7/2026 07:45 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Celldex Therapeutics NASDAQ:CLDX

$41.71 +0.15 (+0.36%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$41.76 +0.05 (+0.13%)

As of 08/7/2026 07:34 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Disc Medicine NASDAQ:IRON

$77.44 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$77.51 +0.07 (+0.09%)

As of 08/7/2026 07:34 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Monopar Therapeutics NASDAQ:MNPR

$119.21 -1.00 (-0.83%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$119.04 -0.17 (-0.15%)

As of 08/7/2026 07:34 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MNPR, CLDX, IRON, and BEAM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MNPR, CLDX, IRON, and BEAM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MNPR, CLDX, IRON, and BEAM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MNPR, CLDX, IRON, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Celldex Therapeutics NASDAQ:CLDX

Disc Medicine NASDAQ:IRON

Monopar Therapeutics NASDAQ:MNPR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MNPR, CLDX, IRON, and BEAM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MNPR, CLDX, IRON, and BEAM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MNPR, CLDX, IRON, and BEAM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MNPR, CLDX, IRON, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Celldex Therapeutics NASDAQ:CLDX

Disc Medicine NASDAQ:IRON

Monopar Therapeutics NASDAQ:MNPR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools